Neurocrine Biosciences | NBIX - Loan Capital

Stock Price
141.78
Daily Change
3.85 2.79%
Monthly
0.82%
Yearly
15.63%
Q1 Forecast
131.87

Neurocrine Biosciences reported $169.5M in Loan Capital for its fiscal quarter ending in March of 2023.





Loan Capital Change Date
AbbVie USD 62.97B 12M Sep/2025
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
ALKERMES USD 285.82M 639K Sep/2024
Alnylam Pharmaceuticals USD 1.04B 13.75M Sep/2025
Amgen USD 52.43B 1.33B Sep/2025
Biogen USD 6.29B 1.4M Sep/2025
BioMarin Pharmaceutical USD 596.66M 501K Sep/2025
Cytokinetics USD 158.75M 554.3M Sep/2025
Dynavax Technologies USD 220.97M 214K Sep/2025
Gilead Sciences USD 22.14B 5M Sep/2025
Halozyme Therapeutics USD 800.07M 709.03M Sep/2025
Incyte USD 35.37M 3.61M Sep/2025
Ionis Pharmaceuticals USD 28.78M 596.71M Sep/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Pfizer USD 57.41B 93M Sep/2025
Prothena USD 0 0 Dec/2024
Regeneron Pharmaceuticals USD 2.71B 720.4M Dec/2025
Repligen USD 537.93M 4.2M Sep/2025
Sarepta Therapeutics USD 1.04B 104.31M Sep/2025
Teva Pharmaceutical Industries USD 14.99B 1.78B Dec/2025
Ultragenyx Pharmaceutical USD 782.75M 11.3M Jun/2025
Vertex Pharmaceuticals USD 111.4M 1.4M Mar/2025